January 9 -- Azur Pharma Limited today announced that it licensed the exclusive U.S. marketing rights for Niravam (alprazolam orally disintegrating tablets), Parcopa (carbidopa-levodopa orally disintegrating tablets), Kemstro (baclofen orally disintegrating tablets) and Fluxid (famotidine orally disintegrating tablets) from UCB. Financial terms were not disclosed.
The details can be read here.
No comments:
Post a Comment